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Pyrrhocoricin and drosocin, representatives of the short, proline-rich antimicrobial peptide
family kill bacteria by inactivating the bacterial heat shock protein DnaK and inhibiting
chaperone-assisted protein folding. The molecular architecture of these peptides features an
N-terminal DnaK-binding half and a C-terminal delivery unit, capable of crossing bacterial
membranes. Cell penetration is enhanced if multiple copies of pyrrhocoricin are
conjugated. To obtain drug leads with improved antimicrobial properties, and possible
utility as therapeutic agents, we synthesized chimeric dimers, in which pyrrhocoricin’s
potent DnaK-binding domain was connected to drosocin’s superior cell penetrating
module. Indeed, the new constructs not only exhibited enhanced in vitro antibacterial
properties against the originally sensitive strains Escherichia coli, Klebsiella pneumoniae and
Salmonella typhimurium, but also showed activity against Staphylococcus aureus, a bacterial
strain resistant to native pyrrhocoricin and drosocin. The improved antimicrobial proﬁle
could be demonstrated with assays designed to distinguish intracellular or membrane
activities. While a novel mixed pyrrhocoricin–drosocin dimer and the purely pyrrhocoricin-
based old dimer bound E. coli DnaK with an identical 4 lM Kd, the mixed dimers
penetrated a signiﬁcantly larger number of E. coli and S. aureus cells than the previous
analogs and destroyed a larger percentage of bacterial membrane structures. Toxicity to
human red blood cells could not be observed up to the highest peptide concentration
tested, 640 lM. In addition, repetitive reculturing of E. coli or S. aureus cells with
sublethal concentrations of the mixed dimer did not result in resistance induction to the
novel peptide antibiotic. The new concept of pyrrhocoricin–drosocin mixed dimers yields
antibacterial peptide derivatives acting with a multiple mode of action, and can serve as a
useful addition to the current antimicrobial therapy repertoire.
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INTRODUCTION
It has been increasingly recognized that native
antibacterial peptides are multifunctional molecules
(Friedrich et al. 2000). In their defense mechanism
insects mainly rely on innate immunity (Boman
1995), when antimicrobial peptides can be detected in
the hemolymph as early as 2–4 h after a septic injury
(Meister et al. 1997). These peptides are remarkably
potent antibacterial compounds. In response to an
experimental infection of Drosophila melanogaster,
the overall hemolymph concentration of eight
inducible antimicrobial peptides reaches high micro-
molar or low millimolar values, half of which is ac-
counted for by the antifungal molecule drosomycin,
and the other half by seven additional antibacterial
or/and antifungal compounds (Uttenweiler-Joseph
et al. 1998). Recent studies suggest that cationic
antimicrobial peptides, once thought to have only
bacterial killing properties, are also potent stimula-
tors of the innate immune system (DiNardo et al.
2003). Peptide LL-37 prevents lipopolysaccharide
(LPS)-induced production of tumor necrosis factor
(TNF)-a in vitro and protects mice from endotoxic
shock (Scott et al. 2002). Additional functions of LL-
37 include being chemotactic for human peripheral
blood neutrophils, monocytes and T-cells (Yang et al.
2000). Due to the inﬂammatory properties of other
types of antimicrobial peptides, the current challenge
is to enhance innate responses without harmful
immunological side eﬀects (Finlay and Hancock
2004).
In the early-mid-90s, cationic antimicrobial pep-
tides were generally described as membrane-active
agents. A direct correlation between antibiotic effect
and membrane disruption has been found for mam-
malian and insect defensins, magainins from frogs
and cecropins from insects (Steiner et al. 1988; Coc-
iancich et al. 1993; Wimley et al. 1994; Ludtke et al.
1995). However the question is still open whether
membrane disintegration is the only mechanism by
which these peptides kill bacteria, the peptides have
various intracellular targets, or if both mechanisms
play roles in the killing process. Individual peptides,
selected from each of the four structural classes of the
antimicrobial peptide families, vary widely in their
ability to depolarize the cytoplasmic membrane
potential of the most frequent test microorganism
Escherichia coli, with certain peptides being unable to
cause depolarization at the minimal inhibitory
concentration (MIC), and others causing maximal
depolarization below the MIC value (Wu et al. 1999).
In support, an increasing number of reports identify
various intracellular functions and macromolecules
as targets of antibacterial peptides (for reviews see
Refs. Andreu and Rivas 1998; Cudic and Otvos 2002;
Devine and Hancock 2002). The truth probably lies
in a multifunctional mode of action. The peptides
ﬁrst enter the bacteria, they either lyse the membrane
or leave the membrane structure intact, depending
upon the ﬁne amino acid composition, and some of
the antibacterial peptides ultimately meet their
intracellular targets (Gallo and Huttner 1998). When
prolines are inserted into the sequences of a-helical
antimicrobial peptides, the peptides’ ability to per-
meabilizing the cytoplasmic membrane of E. coli
decreases substantially as the function of the number
of proline residues incorporated (Zhang et al. 1999).
In this regard, it is intriguing that some of the most
active native antibacterial peptides, at least those
against selected Gram-negative pathogens, belong to
the proline-rich peptide family (Otvos et al. 2000a).
Medium-sized proline-rich antibacterial peptides
have been isolated from Hymenoptera, Lepidoptera,
Hemiptera and Diptera. The most studied members
are drosocin from D. melanogaster (Bulet et al. 1993)
(Table I), pyrrhocoricin from the European sap-
sucking bug Pyrrhocoris apterus (Cociancich et al.
1994), apidaecins from the honeybee (Casteels et al.
1989), and formaecin from the ant Myrmecia gulosa
(Mackintosh et al. 1998). Both native pyrrhocori-
cin and drosocin show some selectivity towards








Where Dab is 2,4-diamino-butyric acid, MeArg is N-methyl-arginine, Pip is 4-amino-piperidine-4-carboxylic acid and Chex is 1-amino-1-
cyclohexane-carboxylic acid.
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Gram-negative organisms, mostly from the Entero-
bacteriaceae family killing E. coli, Salmonella ty-
phimurium, Klebsiella pneumoniae and Agrobacterium
tumefaciens in the mid nM-low lM concentration
range (Bulet et al. 1996; Hoﬀmann et al. 1999).
Additional Gram-negative drosocin susceptible
strains include Enterobacter cloacae and Erwinia ca-
rotovora carotovora. Pyrrhocoricin is active against
Haemophilus inﬂuenzae (Cudic and Otvos 2002). Both
peptides kill the Gram-positive bacterium Micrococ-
cus luteus, and pyrrhocoricin shows weak activity
against two additional Gram positives, Bacillus
megaterium and Aerobacter viridans. The short, pro-
line-rich peptides in their native form do not appear
to kill the major Gram-positive threats to humans,
such as Staphylococcus aureus, Streptococcus pneu-
moniae or Streptococcus pyogenes. They are also
inactive against fungi. A series of small proline-rich
peptides were isolated from bees, and they are col-
lectively called apidaecins (Casteels et al. 1989). These
are 18–20 residue-long peptides with highly conserved
carboxy termini. The N-terminal substitutions fea-
ture both conservative and non-conservative residue
changes. The constant domains are considered
responsible for the general antibacterial activity, and
the variable domains for the bacteria-speciﬁc activity
spectrum. Indeed, huge activity diﬀerences can be
found among the apidaecin peptides, with the pep-
tides from the honeybee killing Yersinia enterocolitica
but not aﬀecting Campylobacter jejuni, and the ana-
logs isolated from the wasps acting in exactly the
opposite way (Casteels et al. 1994).
Based on studies with D-enantiomers, apidaecin,
drosocin and pyrrhocoricin were suggested to act
with a certain stereospeciﬁcity on a bacterial target
protein (Casteels and Tempst 1994; Bulet et al. 1996;
Hoﬀmann et al. 1999). The proposed mechanism by
which apidaecin kills bacteria involves an initial
encounter of peptide with an outer membrane com-
ponent, followed by a speciﬁc and essentially irre-
versible engagement with a receptor/docking
molecule in the cells. In the ﬁnal step, the peptide is
translocated into the cell interior where it meets its
ultimate target, one or more components of the
protein synthesis machinery (Castle et al. 1999).
When identifying the biopolymers involved in this
cascade, we observed that pyrrhocoricin, drosocin
and apidaecin bind to bacterial LPS and the 70 kDa
heat shock protein (Hsp) DnaK in a speciﬁc manner,
while the binding to the 60 kDa bacterial chapero-
nine GroEL is non-speciﬁc (Otvos et al. 2000b). Later
we studied the mechanism of action of the proline-
rich antimicrobial peptides especially that of pyr-
rhocoricin, and their binding sites to E. coli DnaK.
According to these studies, biologically active pyr-
rhocoricin made of L-amino acids inhibits the
ATPase activity of a recombinant form of this Hsp70
variant (Kragol et al. 2001), while the inactive
D-enantiomer or membrane-active antibacterial
peptides such as cecropin A or magainin 2 fail to
inhibit DnaK-mediated phosphate release from ATP.
Pyrrhocoricin and drosocin also inhibit DnaK-med-
iated refolding of nascent proteins in E. coli cells as
opposed to mostly membrane-acting antimicrobial
peptides that do not show this eﬀect (Kragol et al.
2001). A combination of DnaK binding, cell pene-
tration and enzyme inhibition studies identiﬁed Asp2,
Tyr6, Leu7 and Arg9 in pyrrhocoricin as binding sites
to bacterial DnaK, the C-terminal half of the peptide
as the cell penetrating module, and the interspersed
proline residues as a motif responsible for the main-
tenance of structural integrity (Bower et al. 2004).
While pyrrhocoricin shows an increased in vitro
eﬃcacy against Gram-negative bacterial strains than
drosocin, the latter peptide demonstrates a somewhat
broader activity spectrum. These properties are likely
due to the more robust pharmacophore of pyrrhoco-
ricin and the more potent cell-penetrating domain of
drosocin, at least at the monomeric peptide level
(Bencivengo et al. 2001). Slight changes in the peptide
sequence, all including incorporation of additional
positively charged amino acid residues, can change
pyrrhocoricin’s predominant mode of action from
DnaK inhibition to membrane disintegration (Benci-
vengo et al. 2001; Bower et al. 2003). The additional
positive charges promote interaction of the peptide
with bacterialmembranes to apointwhenharmless cell
penetration turns into membrane depolarization. An-
other way to increase the level of peptide interaction
with bacterial membranes and thus, to improve the
antimicrobial properties, is dimerization of the anti-
microbial peptide molecules. Indeed, designer pyr-
rhocoricin dimers, when two peptide molecules are
connected via a C-terminal diamino-carboxylic acid
residue, exhibit markedly improved in vitro antimi-
crobial properties (Cudic et al. 2002). The enhanced
in vitro antibacterial properties are reﬂected in
remarkable in vivo protective eﬀects in mouse models
of pneumonia and pyelonephritis (Cudic et al. 2002;
Cudic et al. 2003). However, even the most active
pyrrhocoricin analog, the Pip-pyrr-MeArg dimer
(Table I), is suboptimal as a clinical candidate as is
indicated in its inability to kill bacteria in full-strength
media used customarily for vigorous propagation of
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bacterial cultures, the broth of choice of the microbi-
ology literature (Cudic et al. 2002; Cudic et al. 2003).
The Pip-pyrr-MeArg dimer exhibits poor in vivo eﬃ-
cacy if systemic bacteremia is induced in mice by
infecting themwith bacterial colonies exceeding 106 cfu
(mortality rather than morbidity).
In the current study we investigate the antimicro-
bial and cell penetration properties of mixed pyrrho-
coricin–drosocin dimers. First, as a practical goal, we
wanted to generate antibacterial peptides with further
improved in vitro eﬃcacy for ensuing pharmaceutical
development. Second, on a purely theoretical basis, we
wanted to document that designer antimicrobial pep-
tides are able to kill bacteria by a dual mode of action:
DnaK inhibition and/or membrane disintegration.
Since bacteria have to modify their genetic composi-
tion to each individual mode of action to develop
resistance to any given antibiotic, such a combinatorial
therapy approach will be extremely useful to ﬁght
bacterial resistance in the long run.
MATERIALS AND METHODS
Peptide Synthesis
Amino acids protected with 9-ﬂuorenyl-methoxy-carbonyl
group (Fields and Noble 1990), were used for peptide synthesis.
The peptide chain assembly was carried out on a Rainin PS3
automated synthesizer. After triﬂoroacetic acid cleavage, peptides
were puriﬁed by reversed-phase high performance liquid chroma-
tography (RP-HPLC) in a water/acetonitrile/triﬂuoroacetic acid
elution system until matrix-assisted laser-desorption/ionization
(MALDI) mass spectra revealed only single species.
Fluorescence Polarization
Recombinant DnaK protein was serially diluted in Tris-buffer
(pH 7.4) in 50 lL ﬁnal volume in 6 · 50 mm disposable glass
borosilicate tubes. The ﬂuoresceinated peptides were added to each
tube in a 50 lL aliquot to a ﬁnal concentration of 1–4 nM and the
tubes were incubated at 37C for 5 min. The extent of ﬂuorescence
anisotropywasmeasuredonaBeacon2000ﬂuorescencepolarization
instrument (PanVera, Madison, WI) and was calculated as millipo-
larizationvalues. The ﬁlters usedwere 485 nmexcitation and535 nm
emission with 3 nm band width. The Kd values were calculated after
curve ﬁtting with non-linear logistical transition by the Levenberg–
Marquardt algorithm within the SlideWrite software package.
Antibacterial Assay
Antibacterial liquid growth inhibition assays were performed
using sterile 96-well plates (Nunc F96 microtiter plates) in a ﬁnal
volume of 100 lL as described previously (Cudic et al. 2002).
Brieﬂy, 90 lL of a suspension of a midlogarithmic phase bacterial
cultures at an initial absorbance at 600 nm of 0.001 in full-strength
or diluted Muller–Hinton Broth (MHB) was added to 10 lL of
serially diluted peptides dissolved in sterilized water. The ﬁnal
peptide concentration was 40 lM. Cultures were incubated at 37C
for 20 h without shaking. Growth inhibition was measured by
recording the absorbance at 600 nm using a microplate reader.
Cell Penetration
In order to study the ability of peptide derivatives to enter
E. coli SEQ102 (ATCC BAA457) or S. aureus 655 (ATCC 27660)
cells ﬂuorescein-labeled peptides were added to bacterial cultures at
ﬁnal concentrations of 5 lg/mL. The cells were allowed to acquire
the peptides for 1 h at 37C. Excess substrate was then removed
and the cells were washed extensively with phosphate buﬀered
saline (PBS), pH 6.8. The cells were ﬁxed with PBS containing 1%
paraformaldehyde and visualized using a Leica TCS SPII laser
scanning confocal microscope. To check for total number of bac-
terial cells from the same preparations, the cells were also detected
with diﬀerential interference contrast microscopy (DIC) and
counted. This technique produces a monochromatic shadow-cast
image (such as shown in Fig. 4) that eﬀectively displays the gra-
dient of optical paths for both high and low spatial frequencies
present in the specimens.
Bacterial Viability Assay
E. coli SEQ102 or S. aureus 655 cells were grown in full-
strength MHB at 37C to midlogarithmic phase. The cells were
then allowed to acquire the peptide for 1 h at 37C. The ﬁnal
concentrations of the peptides were 5 and 20 lM, respectively.
Solutions were treated with 3 lL LIVE/DEAD BacLight
TM
stain
(Molecular Probes Inc., Eugene, OR). Samples were incubated in
the dark for 15 min prior to analysis. Stained samples for
microscopy analysis were passed through 0.2 lm black, polycar-
bonate membrane ﬁlters supported by a 25 mm 0.45 lm mixed
cellulose ester ﬁlter. Bacteria retained on the ﬁlter were then wa-
shed with sterile water to remove any unbound stain. Following the
wash step, the polycarbonate ﬁlters were transferred to a glass
microscope slide. A drop of Vectashield mounting medium was
applied to the ﬁlter. A glass cover slip was then applied. The
microscope slides were photographed with a 100· plan apo 1.4
N.A. oil lens on a Nikon E600 upright microscope with a SPOT
RT Slider digital camera. The images were analyzed using Image
Pro Plus software (MediaCybernetics, Coral Springs, MD).
Hemolysis
One and a half milliliter of human blood was centrifuged at
3000 rpm for 5 min. Ten microliter of the pellet was added to
490 lL PBS to create a 1% red blood cell stock solution. Fifty
microliter of this suspension was mixed with 50 lL of 10 lM–
1.28 mM aqueous peptide solutions and the mixtures were incu-
bated for 1 h at 37C without shaking. After incubation, the cells
were centrifuged again at 3000 rpm for 5 min, and the absorbance
of the supernatant read at 405 and 485 nm.
RESULTS
Antimicrobial Peptide Design and Synthesis
Our current lead compound is the Pip-pyrr-MeArg
dimer (Table I), a dimeric pyrrhocoricin analog
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containing three non-natural amino acid residue
modiﬁcations. To improve cell penetration, native
pyrrhocoricin is dimerized via building the peptide on a
C-terminal 2,4-diamino-butyric acid (Dab) scaﬀold.
The N-terminal valine residue in native pyrrhocoricin
is replaced by 4-amino-piperidine-4-carboxylic acid
(Pip) to avoid aminopeptidase cleavage, decrease
interaction with the conventional substrate-binding
pocket of mammalian Hsp70 (to eliminate high dose
toxicity to infected mammals) and to further improve
bacterial cell penetration (additional positive charge)
(Cudic et al. 2002). The Asn–Arg bond near the
C-terminus is the main pyrrhocoricin cleavage site in
mammalian serum (Hoﬀmann et al. 1999), and to in-
crease the half-life this bond is protected by N-meth-
ylation. In our earlier studies, we optimized the
synthetic details of similar pyrrhocoricin dimers
(Cudic et al. 2002). As single-chain drosocin appears to
exhibit better cell penetrating properties than native
pyrrhocoricin, our initial plan was to prepare the exact
drosocin-based analog of the Pip-pyrr-MeArg dimer.
In spite of our repeated eﬀorts, mass spectroscopy
indicated that our crude products did not contain the
expected peptide species. This coincides with our pre-
vious ﬁndings relative to the synthesis opportunities of
pyrrhocoricin anddrosocin derivatives.Whilemultiple
synthesis of anAla-scan of pyrrhocoricin (Kragol et al.
2002) yielded all analogs in acceptable purity, the
synthesis failed for approximately half of the drosocin
Ala-scan peptides.
Learning from this experience, we decided to
prepare a mixed pyrrhocoricin–drosocin dimer (P–D
construct). In the P–D construct, we retained the N-
terminal 10 residues of the Pip-pyrr design that con-
tains the putative DnaK-binding motif, and added
drosocin’s C-terminal delivery module with the last
arginine N-methylated, MeArg (Table I). Just like for
the Pip-pyrr-MeArg dimer, the P–D construct was
built up on a Dab scaﬀold, which replaced the native
C-terminal Val in drosocin. We made two additional
changes: to further improve cell penetration, the
apparently functionless Ser5 was replaced with the
positively charged Arg and the C-terminal Tyr in
pyrrhocoricin was inserted into the analogous posi-
tion in drosocin (between Ile17 and Arg18) in order
to provide additional contact points to the lipidic
portions of bacterial membranes. Native membrane-
active antimicrobial peptides utilize an alternating
positively charged – hydrophobic residue architecture
to depolarize bacterial membranes (Otvos 2000). In
contrast to the purely drosocin-based dimer, the P–D
construct could be prepared with one dominant peak
on the mass spectrum. However, this peptide species
represented an analog with the MeArg protecting
Mtr group still attached to one of the guanidine side-
chains (4613 m/z compared to the calculated molec-
ular mass of 4403 Da). Repeated triﬂuoroacetic acid
treatments were unable to remove the Mtr group.
Neither our inability to remove one of the MeArg
protecting groups nor the cleavage of the second Mtr
moiety is surprising: the MeArg residue is located
closer to the asymmetrical Dab scaﬀold than does the
analogous MeArg in the parent Pip-pyrr-MeArg di-
mer, and thus is subject of steric hindrance to ensuing
reactions (Urge and Otvos 1995). A second, less
dominant though potentially troubling synthetic
problem for industrial scale production was the
lower-than-average coupling yield of the N-terminal
Fmoc-Pip(Boc)-OH residue.
Therefore in the ﬁnal product, the P–D–A (pyr-
rhocoricin–drosocin–apidaecin) chimera (Table I),
we eliminated the N-methyl backbone protection and
replaced the Pip residue with Chex, 1-amino-1-
cyclohexane carboxylic acid, a cyclic valine mimic
without the extra positive charge in the ring. Pyr-
rhocoricin dimers with Chex as an N-terminal residue
are remarkably active both in vitro and in vivo (Cudic
et al. 2002). To compensate for the loss of a positive
charge, an extra histidine residue was inserted be-
tween the pyrrhocoricin-based N-terminal and the
drosocin-based C-terminal fragments. This idea came
from the antimicrobial activity of pyrrhocoricin and
drosocin analogs, and sequence comparison with the
apidaecins: Thr11 in pyrrhocoricin and drosocin can
be freely substituted without a loss in the antibacte-
rial activity (Kragol et al. 2002), have no apparent
function (Bower et al. 2004), and indeed, are replaced
with His in the apidaecin sequences (Casteels et al.
1989). With its positive charge and hydrophobic
character, His is an ideal residue to increase the
interaction of antimicrobial peptides with bacterial
membrane structures. The synthesis of the P–D–A
chimera proceeded eﬀortlessly in a reproducible
manner, even with single couplings throughout. After
cleavage the expected peptide species (measured
average molecular mass 4647 m/z, compared to a
calculated molecular mass of 4647 Da) could be
puriﬁed in high yield.
Antibacterial Activity In Vitro
The antibacterial activities of the pyrrhocoricin–
drosocin chimeras were tested against four strains of
three Pip-pyrr-MeArg susceptible bacteria, E. coli
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SEQ102, K. pneumoniae K6, K. pneumoniae 1296 and
S. typhimurium S2, as well as against the pyrrhoco-
ricin non-susceptible strain S aureus 655. These
represent historical bacterial strains with early
resistance to selected antibiotics (K. pneumoniae K6,
S. typhimurium S2 and S. aureus 655) and newer
multidrug resistant isolates from the urinary tract of
infected patients (E. coli SEQ102 and K. pneumoniae
1296) (Cudic et al. 2002; Cudic et al. 2003). Anti-
bacterial peptides with intracellular targets are active
only when the assay is run in diluted growth medium,
most likely because the salt content of full-strength
media used to quickly propagate bacterial cultures
blocks the positive charges needed for membrane
interaction and hence cell penetration (Cudic et al.
2002). By the same token, the growth curves without
any antibiotics indicate that bacteria grown in diluted
MHB are not as healthy as they are in full-strength
MHB. Therefore, we tested the eﬃcacy of the pep-
tides in both one-quarter strength MHB and in the
full-strength version. Because all the above-listed test
strains are sensitive to ﬂuoroquinolones and resistant
to b-lactams (Cudic et al. 2002; Cudic et al. 2003),
ciproﬂoxacin was used as positive and amoxicillin as
negative controls.
As found earlier, native pyrrhocoricin was inac-
tive or very weakly active against all strains in full-
strength MHB, and exhibited only mediocre activity
against the Gram-negatives in one-quarter strength
MHB (Table II). The Pip-pyrr-MeArg dimer was
similarly ineﬃcient in full-strength MHB, but killed
Gram-negative Enterobacteriaceae very eﬃciently
when the activity was tested in diluted medium
(Table II and Fig. 1). In line with DnaK disintegra-
tion as a predominant mode of action, this pyrrho-
coricin-based dimer was inactive against S. aureus, a
strain that does not share DnaK protein sequence
homology with E. coli at the pyrrhocoricin-binding
D–E helix region. It needs to be mentioned that na-
tive, single-chain drosocin is similarly inactive against
S. aureus strains in both full-strength and diluted
media (Bulet et al. 1996). The pyrrhocoricin–drosocin
dimer chimeras demonstrated superior activity
against Enterobacteriaceae even in full-strength
MHB. Their activity against E. coli was indistin-
guishable in full-strength or diluted media indicating
that penetration into E. coli cells was not inhibited
any longer. While they could not kill S. aureus in full-
strength MHB, they exhibited good activity in one-
quarter strength MHB (Fig. 2), an ambition none of
our previous pyrrhocoricin or drosocin derivatives
could achieve. This was our ﬁrst indication that the
pyrrhocoricin–drosocin chimeras kill bacteria with a
mode of action diﬀerent than that utilized by other
proline-rich antibacterial peptides. If any distinction
can be made, the P–D–A chimera appeared to be
slightly more active than the P–D construct.
DnaK Binding
Our next goal was to document that the superior
antimicrobial properties of the P–D–A chimera
compared to the Pip-pyrr-MeArg dimer was due to
better binding to the target DnaK protein. N-termi-
nally ﬂuorescein-labeled derivatives of these peptides
were incubated with recombinant E. coli DnaK and
the binding was recorded on a ﬂuorescence polar-
imeter. Both antibacterial peptide derivatives bound
E. coli DnaK in a concentration-dependent manner
(Fig. 3). The Kd values of this set of assays, equally
around 4 lM, are almost identical to that we ob-
tained earlier for the Pip-pyrr-MeArg dimer – E. coli
Table II. Minimal Inhibitory Concentrations (in lM) of Antibiotics Against Various Pathogens
Bacterial strains














Pyrrhocoricin >40 10 >40 40 >40 >40
Pip-pyrr-MeArg dimer 20 1.2 >40 2.5 >40 >40
P–D construct 5 2.5 20 5 >40 10
P–D–A chimera 2.5 5 10 2.5 >40 5
Amoxicillin >40 >40 >40 >40 >40 >40
Ciproﬂoxacin <0.3 <0.3 <0.3 <0.3 <0.3 <0.3
The liquid growth inhibition assays were run in full-strength or diluted Muller–Hinton broth overnight at 37C. The MIC values of the
dimeric pyrrhocoricin–drosocin–apidaecin chimera against the multidrug resistant strains K. pneumoniae 1296 and S. typhimurium S2 in full-
strength MHB are 20 and 2.5 lM, respectively.
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DnaK interaction (approximately 3.5 lM, Ref.
Bower et al. 2003). The minor alteration in the Kd
ﬁgure from assay to assay reﬂects solubility problems
of pyrrhocoricin – DnaK protein complexes during
in vitro biological assay conditions (Chesnokova
et al. 2004). We also attempted to record binding of
the same ﬂuorescein-labeled peptides to synthetic
E. coli or S. aureus DnaK D–E helix fragments, but
no ﬂuorescence anisotropy could be observed. This
was not surprising as in this case, as opposed to our
earlier assays with smaller, monomeric peptides
(Kragol et al. 2002), the size of the tracer exceeded
the size of the test compound, and little, if any,
change in the spinning speed of the ﬂuorescein-
labeled tracer could be expected after mixing and
upon peptide–peptide binding.
Entry into Bacterial Cells
For measuring the level of cell penetration, we
used two microscopy techniques. Upon incubation
with bacteria, N-terminal ﬂuorescein-derivatives en-
ter cells and stain all the compartments where they
are distributed. Homogenous cell staining indicates
full penetration, labeling only the cell surface indi-
cates temporary, weak interactions with the phos-
pholipid bilayer. In the dual ﬂuorochrome assay
bacteria are incubated with the test compounds and
Fig. 1. In vitro activity of pyrrhocoricin dimers and control antibiotics against Klebsiella pneumoniae K6. The standard broth dilution
susceptibility assay was run in full-strength Muller–Hinton broth overnight at 37C.
Fig. 2. In vitro activity of pyrrhocoricin dimers and control antibiotics against S. aureus 655. The standard broth dilution susceptibility assay
was run in one-quarter strength Muller–Hinton broth overnight at 37C.
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are stained for healthy or damaged membranes.
Thus, this measure is a reﬂection of the ability of the
test compounds to cause leakage in the membrane
structure. Both assays were used to identify differ-
ences in the activity of the P–D–A chimera and the
Pip-pyrr-MeArg dimer on bacterial membranes. In
the cell penetration assay, the ﬂuorescein-labeled Pip-
pyrr-MeArg dimer stained approximately 30% of
E. coli cells (Fig. 4). For the P–D–A chimera this
value was close to 100%, indicating a signiﬁcantly
increased ability of the pyrrhocoricin–drosocin
mixed dimer to penetrate bacteria than the purely
pyrrhocoricin-based analog. For S. aureus, the cell
penetration values were 3% and 10% for the Pip-pyrr-
MeArg dimer or the P–D–A chimera, respectively.
The ability of the peptides to enter bacteria was
identical regardless of whether the cells were grown
individually or clumped together (Fig. 4). Every cell
penetrated was stained homogenously, indicating full
distribution in the intracellular milieu. While Fig. 4
shows only one-piece cells for quantitation of the
results, many fully damaged cells, destroyed by the
antimicrobial peptides, could be observed under the
microscope. The number of dead cells was higher
when cultures were treated with the P–D–A chimera
compared with the Pip-pyrr-MeArg dimer.
The direct effect of the test peptides on bacterial
membranes was studied by the dual ﬂuorochrome
membrane viability assay. This system provides a
method to distinguish between bacteriawith healthy or
damaged membrane structure. The kit utilizes mix-
tures of the SYTO 9 green-ﬂuorescent (peak excitation
wavelength 480 nm, peak emission wavelength
500 nm) nucleic acid stain and the red-ﬂuorescent
(peak excitation wavelength 490 nm, peak emission
wavelength 635 nm) nucleic acid stain, propidium io-
dide. These stains differ both in their spectral charac-
teristics and in their ability to penetrate bacterial cells.
When used alone, the SYTO 9 stain generally labels all
bacteria in a population, those with intact membranes
and those with damaged membranes. In contrast,
propidium iodide penetrates only bacteria with dam-
aged membranes, causing a reduction in the SYTO 9
stain ﬂuorescent when both dyes are present. The ratio
of the green and red stained cells can be quantitatively
analyzed. Once again, the P–D–A chimera was sig-
niﬁcantly more successful than the Pip-pyrr-MeArg
dimer to depolarize E. coli or S. aureus bacterial
membranes (Fig. 5). In our speciﬁc experimental
Fig. 3. Binding of N-terminally ﬂuorescein-labeled peptide dimers
to recombinant E. coli DnaK protein. The interaction of the pep-
tides and the protein was studied by ﬂuorescence polarization.
Fig. 4. Penetration of ﬂuorescein-labeled peptides into E. coli SEQ102 and S. aureus 655 cells. The peptides entered the cells and became
homogenously distributed in the intracellular space. Percentage of cells containing labeled peptides was calculated based on the total number
of cells identiﬁed by diﬀerential interference contrast.
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conditions, the percentage of cells with damaged
membranes upon treatment with the Pip-pyrr-MeArg
dimer was 35% (E. coli) and 36% (S. aureus). This
level of membrane disintegration by itself would not
be enough for complete killing of the bacteria.
However, the growth of E. coli cultures is inhibited at
the applied 5 lM concentration (Table II) indicating
that the inhibition of an intracellular target, in our
case the DnaK protein, is suﬃcient to complete the
killing process. The P–D–A chimera caused 50%–
61% membrane damage to E. coli cells and 52%
damage to S. aureus, apparently enough to destroy
both bacterial cultures (Table II). Because pyrrho-
coricin does not bind to S. aureusDnaK (Kragol et al.
2002), all these data suggested that killing of S. aureus
cultures by the pyrrhocoricin–drosocin mixed dimer
proceeded through membrane disintegration.
Additional Pharmacological Parameters: Toxicity,
Stability, Resistance Induction
In addition to effective killing of bacteria, novel
antimicrobials have to show positive pharmacologi-
cal properties, such as lack of toxicity and resistance
induction as well as appropriate stability in biological
media. Antimicrobial peptides inhibiting bacterial
growth by depolarizing the membrane, such as the
cecropins and magainins fall short in one or more of
these categories. In particular, excessive activity on
bacterial membranes often goes hand in hand with
toxicity to mammalian cells (Bower et al. 2003). We
also speculated that bacteria can alter their mem-
brane composition to evade the activity of mem-
brane-acting antimicrobial peptides (Cudic et al.
2003). To assess peptide eﬀects on eukaryotes in vitro,
we measured mammalian cell toxicity on freshly ac-
quired human red blood cells. In this assay, none of
the peptide monomer or dimers (native pyrrhocori-
cin, Pip-pyrr-MeArg dimer, P–D construct or P–D–A
chimera) was toxic up to the highest concentrations
studied, usually 640 lM (Table III). In contrast,
magainin 2 caused hemolysis at 160 lM, near a
peptide concentration that was identiﬁed as toxic to
the mouse kidney-originated COS-7 cells (Cudic et al.
2003). The positive control bee venom mellittin
proved to be toxic at 5 lM, the lowest concentration
we used in the assay. In a signiﬁcant achievement, the
observed increased level of penetration into bacterial
cells by the pyrrhocoricin–drosocin mixed dimers did
not result in noticeable toxicity to mammalian cells.
Calculating with a maximum of 3 mg/kg therapeutic
dose (60 lg per mouse) intravenously, if developed as
drug candidates, these analogs will oﬀer a remarkable
therapeutic index of at least 100.
Although the pyrrhocoricin–drosocin mixed di-
mers are the most active short, proline-based anti-
microbials to date, they might be the source of
currently non-existent resistance mechanisms. To
study this possibility, E. coli and S. aureus were
co-cultured once daily for 10 days with sublethal
doses of the P–D–A chimera. The induction of
resistant mutants, as indicated by the increase of the
Fig. 5. Activity of the Pip-pyrr-MeArg dimer and the P–D–A chimera on the membrane structure of E. coli SEQ102 and S. aureus 655 cells.
The green stain marks cells with intact membranes; red indicates those with damaged membranes.
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MIC values, was studied after passage 5 and 10 not
only against the co-culturing antibiotic peptide, but
also against a series of other pyrrhocoricin-based or
conventional antimicrobial compounds. As Table IV
shows, the activity of neither peptidic nor conven-
tional antibiotics changed signiﬁcantly against either
bacteria, suggesting that the improved activity on the
cell membrane did not induce major alterations in
those regions of the bacterial genome where the test
antibiotics exert their activity. These data also indi-
cate that a P–D–A chimera therapy can be followed
by treatment with conventional antibiotics if needed
without any loss of the potency of the non-peptidic
antimicrobials. The day 5 data varied slightly with
magainin 2 and kanamycin, on both parallel plates. If
this variability was not due to the natural error of the
liquid growth inhibition assay, it would indicate that
the strong eﬀect of the P–D–A chimera on the
membrane actually may induce some membrane-
associated resistance that deactivated the other
membrane disintegrating peptide antibiotic, magainin
2. In this regard, it is interesting to note that the
P–D–A chimera remained fully active against
S. aureus, for which the second killing mechanism,
DnaK inhibition is non-existent. The diﬀerences are
probably found in the way magainin 2 and the
pyrrhocoricin–drosocin dimers insert into bacterial
membranes. While the proline-less magainin forms
a-helices in a membrane environment (Wieprecht et
al. 2000), the proline-rich peptides pyrrhocoricin or
drosocin are unable do so (McManus et al. 1999;
Otvos 2000), and it is unlikely their dimeric variants
would.
The only problem with the pyrrhocoricin–droso-
cin chimeras of this report is their low stability in
mammalian sera. In our previous study we explained
the lack of in vivo eﬃcacy of native drosocin with the
fast decomposition in mouse serum (Hoﬀmann et al.
1999). Actually, we selected pyrrhocoricin for further
studies because this peptide shows improved serum
stability. In the current study, the purely pyrrhoco-
ricin-based analog, the Pip-pyrr-MeArg dimer, did
not lose any in vitro eﬃcacy against E. coli (in either
1/4 or full-strength MHB) and retained some activity
against S. typhimurium when 25% human serum was
added to the wells of the liquid growth inhibition
assay, the P–D construct or the P–D–A chimera lost
a signiﬁcant amount of eﬃcacy against E. coli and
became inactive against S. typhimurium or S. aureus
(Table V). Apparently N-methylation of the C-ter-
minal arginine, a major cleavage site in native pyr-
rhocoricin and drosocin (Hoﬀmann et al. 1999) did
not help improve the serum stability. Overall the P–D
construct with backbone protection was no more
resistant than the P–D–A chimera lacking a methy-
lated amide bond.
Table III. Toxicity of Antimicrobial Peptides to Human Red
Blood Cells







Peptides were incubated with a 1% erythrocyte suspension and the
absorbance of the supernatant was measured at 405 and 485 nm.
Table IV. Minimal Inhibitory Concentrations (MIC) of Antimicrobials (in lM) when Bacteria were Repeatedly Cultured with Sublethal
Doses of the P–D–A Chimera
Antibiotic
MIC (lM)
Day 0 Day 5 Day 10
E. coli S. aureus E. coli S. aureus E. coli S. aureus
P–D–A chimera 5 2.5 5 10 5 2.5
Pyrrhocoricin >40 >40 20 >40 40 >40
Pip-pyrr-MeArg dimer >40 >40 40 >40 20 >40
Magainin 2 40 40 20 5 >40 40
Kanamycin 10 0.6 0.6 <0.3 10 0.3
Erythromycin >40 40 >40 >40 >40 >40
Amoxicillin >40 >40 >40 20 >40 20
Ciproﬂoxacin <0.3 <0.3 <0.3 <0.3 <0.3 <0.3
Escherichia coli SEQ102 (full-strength MHB) and Staphylococcus aureus 655 (1/4 strength MHB) strains were subcultured daily with 1.25 and
2.5 lM P–D–A chimera, respectively, and the activity of various antibiotics against the mutated strains was determined in day 0, day 5 and
day 10. Increase of the MIC values indicate resistance induction.
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DISCUSSION
Broad-spectrum antimicrobial peptides were once
considered viable therapeutic agents, and indeed
cleared different clinical trial phases (Zasloff 2002).
These peptides generally kill bacteria by disintegrat-
ing the membrane structure. Their selectivity to bac-
teria originates from the diﬀerences between
prokaryotic and eukaryotic cell structures. The
interaction of most cationic peptides with eukaryotic
membranes is inhibited by the lack of negatively
charged lipids on the cell surface, by the rather low
negative membrane potential that exists across the
plasma membrane and also by the presence of cho-
lesterol. In contrast, bacterial membranes are abun-
dant in anionic surface phospholipids, have high
negative transmembrane potential and lack choles-
terol as a stabilizing force (Hancock and Scott 2000).
However the moderate clinical success and thera-
peutic index of broad-spectrum antimicrobial pep-
tides has made the pharmaceutical industry less than
enthusiastic about peptide antibiotics, even if new
indications, such as immune stimulatory activities
may give a second life to these lead molecules
(Bowdish et al. 2004). Interest has slowly shifted to
peptides acting on intracellular bacterial targets
(Cudic and Otvos 2002) although inactivation of
bacterial macromolecules can restrict the pool of
peptide-susceptible bacterial strains due to potential
sequence modiﬁcations of the target proteins (Gen-
naro et al. 2002). As attractive as the inactivation of
intracellular macromolecules is, the current report
documents that penetration into bacterial cells is still
the rate-limiting step. Pyrrhocoricin is the prototype
peptide antibiotic acting inside bacterial cells, but
even the most potent purely pyrrhocoricin-based
derivative, the Pip-pyrr-MeArg dimer, is inferior to
the mixed dimers in killing bacteria in vitro. Drosocin
possesses a more aggressive cell-penetrating unit but
a less active DnaK-binding domain (Bencivengo et al.
2001), and these structural diﬀerences among native
antimicrobial peptides are probably due to the iden-
tity of the invading pathogens that the ﬂies (D. mel-
anogaster) or the true bugs (P. apterus) have to
conquer. The suboptimal pharmacological properties
of the P–D–A chimera can be improved by either
stabilizing the sensitive bonds, or by selecting another
delivery module, from a third insect-derived antimi-
crobial peptide.
Whatever sequence the ﬁnal selection will have, it
is probably safe to say that the dimeric structure of
the chimera has to be retained. On one hand, pyr-
rhocoricin dimers show reproducibly better cell pe-
netrating properties, hence antimicrobial activities
than monomers (Cudic et al. 2002). On the other, a
monomeric pyrrhocoricin–drosocin chimera, made
up from the N-terminal DnaK-binding half of pyr-
rhocoricin and the C-terminal delivery module of
drosocin is less active than the native constituents
alone (Bencivengo et al. 2001). The dimeric structure
is likely to provide multiple attachment points to
bacterial phospholipids and promote cell entry.
Whether the utilized diamino-butyric acid scaﬀold is
the ideal selection to achieve this goal remains to be
seen. As far as the rest of the non-natural amino acid
residues is concerned, our current studies show that
methylation of the C-terminal arginine in drosocin
does not seem to improve the serum stability and can
be eliminated. Likewise, when the general membrane
penetrating ability is high, we found little utility in the
positive charge in the ring of the amino-piperidine-
carboxylic acid residue, and the much simpler cyclic
valine mimic amino-cyclohexane carboxylic acid ap-
pears to work just ﬁne. Having said this, a non-nat-
ural amino acid residue cannot be fully eliminated
from the amino terminus in order to avoid non-spe-
ciﬁc interaction with the conventional substrate-
binding pocket of Hsp70 proteins. Although
pyrrhocoricin binds at least 4–5-fold more strongly to
the bacteria-speciﬁc D–E helix site than to the
Table V. Reduction of the Antimicrobial Activity of Dimeric Pyrrhocoricin Derivatives in the Presence of 25% human Serum
Minimal inhibitory concentration in lM when no serum is added / in the presence of 25% human serum against various strengths of E. coli
SEQ102, S. typhimurium S2 or S. aureus 655 MHB
E. coli SEQ102
S. typhimurium S2 S. aureus 655
Full-strength MHB 1/4 strength MHB Full-strength MHB 1/4 strength MHB
P–D–A chimera 2.5/10 2.5/40 2.5/>40 5/>40
P–D construct 2.5/40 2.5/10 10/>40 5/>40
Pip-pyrr-MeArg dimer 10/10 0.6/0.6 5/40 >40/>40
The assays were run on single plates, in conditions identical to those representing Figs. 1 and 2 and Table II.
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non-speciﬁc pocket, interaction of pyrrhocoricin with
all Hsp70 proteins through interaction with the evo-
lutionally conserved substrate-binding pocket is al-
ways a concern (Chesnokova et al. 2004). Such an
interaction can lead to toxicity to the host when heat
shock protein production is upregulated upon bac-
terial infection (Kragol et al. 2002).
Indeed, nature designed the native antibacterial
peptides to bind many macromolecular structures
and surfaces. The alternating hydrophobic-cationic
residue architecture and the dimeric composition al-
lows maximum interaction with the bipolar phos-
pholipid layer of bacterial membranes. Yet the same
architecture makes these peptides very sticky com-
pounds and this structural feature often hinders as-
says designed to evaluate peptide–peptide binding
reactions. As ﬂuorescence polarization could not be
used to quantitate the binding strength of labeled
dimers to the synthetic D–E helix fragments of E. coli
and S. aureus DnaK (see Results), we tried the
opposite, looking for antibacterial peptide dimer
binding to biotin-labeled DnaK fragments. However,
the sticky nature of the dimers prevented these ef-
forts. Regardless of whether we used biotin-labeled
DnaK fragments as capture molecules on streptavi-
din-coated Ciphergen chips, or detectors during
Western-blotting, peptide–peptide binding was
repeatedly detected in not only those cases when
biological results did not support any interaction (e.g.
the Pip-pyrr-MeArg dimer to S. aureus DnaK D–E
helix), but even to blank Ciphergen chips or unrelated
control peptides (e.g. a p53 tetramerization domain)
on the Western-blot. Therefore, to document dimer
binding to DnaK, we have to rely on the study
involving the full protein shown here in Fig. 3. Be-
cause both the Pip-pyrr-MeArg dimer and the P–D–
A chimera bound E. coli DnaK in a highly similar
manner (with an identical Kd of 4 lM), with the latter
peptide signiﬁcantly more active against E. coli cul-
tures in full-strength MHB, we conclude that while
the Pip-pyrr-MeArg dimer kills bacteria only inacti-
vating DnaK, the P–D–A chimera additionally de-
stroys the bacterial membrane structure. The activity
against S. aureus, a bacterium which possesses a
DnaK sequence unsuitable to bind pyrrhocoricin
(Kragol et al. 2001, 2002) supports this hypothesis.
One potential additional way to tell whether
killing microorganisms proceeds through membrane
disintegration or inhibition of intracellular targets is
the measurement of the kinetics of the growth inhi-
bition reaction. While rapid killing indicates mem-
brane depolarization, killing over an extended period
of time is a sign of inhibition of intracellular target
molecules. Drosocin, for example, in this measure
inhibits bacterial growth only after 6 h of treatment
as opposed to diptericin, a more distant family
member with a high glycine content that kills bacteria
within 45 min (Cudic et al. 1999). The original report
on pyrrhocoricin used peptide material isolated from
insects, disk growth inhibition assay and the labora-
tory strain E. coli D22 (Cociancich et al. 1994) to
detect antimicrobial activity only 6 h after peptide
addition, with full killing over a 24-h period. E. coli
D22 has a compromised outer membrane structure,
which is clearly diﬀerent from that of clinical isolates,
such as the urinary-tract infection originated E. coli
SEQ102, a strain that developed resistance to non-
peptidic antibiotics (Cudic et al. 2003). In our hands,
the ﬁrst time point when the liquid growth inhibition
assay presented quantiﬁable growth of E. coli
SEQ102 or S. aureus 655 was 2 h; however by that
time period all pyrrhocoricin-based antibacterial
peptides killed the bacteria (in cases when they would
kill overnight). While with this assay we could not
identify diﬀerences in the mode of action of the var-
ious pyrrhocoricin-based antimicrobials, we were
able to more accurately estimate the killing period,
which is less than 2 h. This time period is still enough
to inhibit DnaK-associated protein refolding in bac-
terial cells as indicated by assaying the enzymatic
activity of E. coli cultures (Kragol et al. 2001).
Drosocin’s improved cell penetrating properties
can be used for delivery of peptidic and non-peptidic
drug leads into cells. Recently we showed that the
Pip-pyrr-MeArg chimera enters a long range of bac-
terial and mammalian cells and is a useful delivery
vehicle of peptide epitopes into dendritic cells (Otvos
et al. 2004). While neither the antibacterial peptide
derivative nor a cytotoxic T cell epitope alone acti-
vated human dendritic cells, a construct made of
these two constituents resulted in the appearance of
maturation markers in 65% of the dendritic cells
studied. We explained these ﬁndings with the ability
of the strongly cationic Pip-pyrr-MeArg dimer to
utilize the less abundant (than in bacteria), but still
present negative charges on the eukaryotic cell sur-
face to enter mammalian cells via passive transport
(Otvos et al. 2004). Alternatively, the antibacterial
peptide can collect extracellular Hsp70 and enter cells
through interaction with the Hsp70 receptor CD91
molecules abundant on the surface of immune cells
(Srivastava 2002) and thus, active transport. In any
event, the improved bacterial cell penetrating abilities
of the pyrrhocoricin–drosocin mixed chimeras are
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likely to represent further improved drug delivery
properties into eukaryotes and across epithelial cell
layers. The only disadvantageous feature of drosocin-
based peptides, the low stability in biological media,
can actually come in handy if used as drug delivery
vehicles. We had to pay special attention to select
linkers between the peptide epitopes and the anti-
bacterial peptide delivery units that are cleavable in
the intracellular milieu, after cell penetration is
completed (Otvos et al. 2004). With the observed
rapid degradation of drosocin derivatives, they may
serve as self-destroying drug delivery modules.
In summary, here we present a new concept for
antibacterial peptides. With chimeras designed to kill
bacteria by a combination of DnaK inhibition and
membrane disintegration we managed to identify a
class of antimicrobials that kill bacteria with a dual
mode of action. Such combinatorial effect not only
improves the activity spectrum and efﬁcacy of the
short, proline-rich antibacterial peptide family, but
represents a treatment option against bacterial strains
that are prone to develop resistance to individual
antimicrobial agents.
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